Abstract:Most esophageal cancers are at a fairly advanced stage at the time of diagnosis, and curative therapy is not possible. For those that are detected early, cure may be possible, particularly if there is no lymphatic spread. Radical therapeutic approaches result in increased treatmentrelated mortality, high treatment-induced morbidity, and reduced quality of life. Therefore it is one of the major targets in the treatment of esophageal cancers to classify the tumor and to perform adequate stage-related therapy. The modern diagnositic procedures, such as endoscopy, endoluminal sonography, computed tomography (CT) scanning, and endoscopic biopsy, have led to major advances in preoperative staging. Endoluminal sonography is able to predict the depth of tumor infiltration in the esophageal wall and the existence of local lymph node metastasis, whereas CT scanning demonstrates distant metastasis. Histologic classification of the tumor together with genetic and cell biologic characteristics can predict the prognosis. Currently, the best prospect for cure of early esophageal cancer is surgical resection through the abdominothoracic approach, although less radical surgical procedures such as transhiatal resection without extensive lymph node dissection seem to achieve the same results. Even less traumatic is the use of minimal invasive techniques, which certainly will be used more often in the future. For early esophageal cancers limited to the epithelium and the lamina propria, local destruction of the tumor leads to long-term survival and cure. Techniques such as endoscopic resection, laser coagulation, photodynamic laser activation and argon beam exposure have been described and seem to achieve similar results. Another conservative method for treating early esophageal tumors is radiotherapy, although it has been shown in several studies that radiochemotherapy is superior to radiotherapy alone, at least in more advanced cases. In future, treating local early esophageal tumors will consist in exact preoperative staging followed by a surgical therapy that includes local excision of tumors limited to epithelium or a more aggressive approach if advanced infiltration of the esophageal wall has been proved. In these cases combined radiochemotherapy plus surgery is promising. In cases with increased operative risk the combination of local tumor destruction plus radiocheotherapy may improve the results.

[Esophageal cancer: standards and innovations in multidisciplinary treatment]

Esophageal cancer: patient evaluation and pre-treatment staging

Recent progress in multidisciplinary treatment for patients with esophageal cancer

Esophageal cancer: The latest on chemoprevention and state of the art therapies

A rationale multidisciplinary approach for treatment of esophageal and gastroesophageal junction cancer: Accurate review of management and perspectives

[Esophageal cancer: new developments in prevention and therapy]

Advances and challenges in the treatment of esophageal cancer

Advances in targeted therapy for esophageal cancer

Advances in targeted therapy and immunotherapy for esophageal cancer

Endoscopic palliation of advanced esophageal cancer

Esophageal cancer: Recent advances in screening, targeted therapy, and management

Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer

Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy

Esophageal cancer, early disease: Diagnosis and current treatment

Current state of the art: immunotherapy in esophageal cancer and gastroesophageal junction cancer

Developments in Treatment of Esophageal/Gastric Cancer

Immunotherapy for Esophageal Cancer: State-of-the Art in 2021

Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects

Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction